KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Japan flag Japan · Delayed Price · Currency is JPY
1,666.00
-4.00 (-0.24%)
Feb 13, 2026, 3:30 PM JST
Market Cap95.94B +15.8%
Revenue (ttm)133.26B +9.6%
Net Income10.77B +179.9%
EPS187.40 +179.9%
Shares Out57.45M
PE Ratio8.91
Forward PE21.07
Dividend52.00 (3.12%)
Ex-Dividend DateMar 30, 2026
Volume71,400
Average Volume115,225
Open1,672.00
Previous Close1,670.00
Day's Range1,651.00 - 1,676.00
52-Week Range1,331.00 - 1,698.00
Beta-0.08
RSI68.55
Earnings DateFeb 4, 2026

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agen... [Read more]

Sector Healthcare
Founded 1923
Employees 1,998
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4569
Full Company Profile

Financial Performance

In fiscal year 2025, KYORIN Pharmaceutical's revenue was 130.09 billion, an increase of 8.83% compared to the previous year's 119.53 billion. Earnings were 9.09 billion, an increase of 70.73%.

Financial Statements